Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2025 11:51 ET | Source: Azurity Pharmaceuticals

Azurity Pharmaceuticals Announces FDA Approval of JAVADIN™ (clonidine hydrochloride) Oral Solution

Woburn, MA, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Javadin™ (clonidine hydrochloride) oral...
October 23, 2025 07:00 ET | Source: George Medicines

TRIDENT, a dedicated stroke outcomes trial in patients with a history of intracerebral hemorrhage (ICH), demonstrates the potential advantages of intensive blood pressure treatment with low-dose triple combination therapyTRIDENT, a dedicate

GMRx2 significantly reduced the risk of recurrent stroke when added to standard of care compared to placeboTrial results were presented during a plenary session of the World Stroke Congress 2025...
October 02, 2025 07:00 ET | Source: George Medicines

George Medicines strengthens global commercialization strategy for GMRx2 with exclusive Biolab Farmacêutica licensing agreement in Brazil

Biolab Farmacêutica gains exclusive rights in Brazil to GMRx2, an innovative single pill combination of three medicines, including two doses that are lower than those currently available in single...
September 18, 2025 01:30 ET | Source: ONWARD Medical NV

Concurrent Publications in Nature and Nature Medicine Highlight Advances in Blood Pressure Regulation after Spinal Cord Injury Using ONWARD ARC-IM Therapy

Detailed results from clinical feasibility studies show immediate improvement in blood pressure stability and durable reduction of hypotensive symptoms, resulting in improved quality of life Most...
July 21, 2025 07:00 ET | Source: George Medicines

George Medicines signs exclusive licensing agreement with Azurity Pharmaceuticals to commercialize WIDAPLIK™ (telmisartan, amlodipine and indapamide) tablets in the US

George Medicines signs exclusive licensing agreement with Azurity Pharmaceuticals to commercialize WIDAPLIK™ (telmisartan, amlodipine and indapamide) tablets in the US An innovative single pill...
June 09, 2025 07:00 ET | Source: George Medicines

George Medicines announces FDA approval of WIDAPLIK™ (telmisartan, amlodipine and indapamide), a new single pill combination treatment for hypertension in adults, including initial treatment

Novel, single pill, triple combination with a standard dose and two lower doses that can deliver the efficacy benefits of combination therapy, with an established safety profile and good...
April 23, 2025 13:02 ET | Source: Alameda Health System

Alameda Health System launches Canine Visitation Program to boost patient and staff well-being

Therapy dogs are traveling the halls of Alameda Health System's hospitals, providing comfort to patients and staff alike.
February 03, 2025 07:00 ET | Source: George Medicines

George Medicines appoints Amy Carroll as Senior Vice President of Medical Affairs

George Medicines appoints Amy Carroll as Senior Vice President of Medical Affairs London, UK, 3 February 2025 – George Medicines, a late-stage biopharmaceutical company focused on addressing...
January 13, 2025 07:00 ET | Source: George Medicines

George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Colombia and Central America

George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Colombia and Central AmericaBausch Health gains exclusive rights to single-pill triple...
December 11, 2024 06:59 ET | Source: Polaris Market Research & Consulting LLP

Blood Pressure Cuffs Market Worth USD 2,312.42 Million by 2034, To Register A CAGR of 8.9% from 2025 to 2034 | PMR

New York, USA, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Market Overview The market for blood pressure cuffs is poised to exhibit a robust CAGR of 8.9% from 2025 to 2034. The blood pressure cuffs market...